Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK

被引:0
作者
C. Canavan
J. Eisenburg
L. Meng
K. Corey
C. Hur
机构
[1] Nottingham University,Division of Epidemiology and Public Health
[2] Massachusetts General Hospital,Institute for Technology Assessment
[3] Massachusetts General Hospital,Gastrointestinal Unit
来源
Digestive Diseases and Sciences | 2013年 / 58卷
关键词
Hepatitis C; Liver fibrosis; Hepatocellular carcinoma; Screening; Health economics; Outcomes research; Radiology/imaging;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2691 / 2704
页数:13
相关论文
共 225 条
[1]  
Argeudas MR(2003)Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis Am J Gastroenterol 98 679-690
[2]  
Chen VK(2012)Is hepatitis C virus carcinogenic? Gastroenterology 142 1274-1278
[3]  
Eloubeidi MA(1996)Poynard T and the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C Hepatology. 24 289-293
[4]  
Fallon MB(2003)Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population J Am Med Assoc 290 228-237
[5]  
Lemon SM(2008)Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 418-431
[6]  
McGiven DR(1997)Estimates of the cost effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C Ann Intern Med 127 855-865
[7]  
Bedossa P(2001)Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 34 809-816
[8]  
Salomon JA(2009)Cost-effectiveness of pegylated interferon and ribivarin for patients with chronic hepatitis C treated in routine clinical practice Int J Technol Assess Health Care. 25 171-180
[9]  
Weinstein MC(2011)Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C Value Health 14 1068-1077
[10]  
Hammitt JK(1997)Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 463-472